Myths, facts and controversies in the diagnosis and management of anaphylaxis

Katherine Anagnostou,1,2 Paul J Turner3

ABSTRACT
Anaphylaxis is a serious systemic allergic reaction that is rapid in onset and may cause death. Despite numerous national and international guidelines and consensus statements, common misconceptions still persist in terms of diagnosis and appropriate management, both among healthcare professionals and patient/carers. We address some of these misconceptions and highlight the optimal approach for patients who experience potentially life-threatening allergic reactions.

INTRODUCTION
Anaphylaxis is a serious systemic allergic reaction that is rapid in onset and may cause death. Recent data suggest that the incidence is increasing, particularly to food. The lifetime prevalence of anaphylaxis is estimated to be between 0.5% and 2%. Despite numerous national and international guidelines, misconceptions continue to persist among both healthcare professionals and patients/carers, which result in under-recognition and suboptimal management of this medical emergency. In this review, we address some of these misconceptions and highlight areas of best practice.

Myth 1: ‘Anaphylaxis often results in death’
Anaphylaxis can be life-threatening, but in reality the majority of reactions do not result in severe outcomes. Many reactions are not treated appropriately (discussed below), yet fatal anaphylaxis is (fortunately) a rare event, with a case fatality rate under 0.001%. Severe anaphylaxis, however, is unpredictable, and severe reactions may mimic more mild anaphylaxis reactions in the first instance. Delay in appropriate treatment almost certainly contributes to fatalities. Therefore, it is critical that all anaphylaxis reactions are treated as a medical emergency.

While hospitalisations in the UK and elsewhere due to anaphylaxis have increased over the last two decades, there has been no increase in fatalities. For the food-allergic individual, the incidence of fatal anaphylaxis is 1.81 per million person years—less than death due to accidental causes or murder. Nonetheless, this needs to be interpreted appropriately: allergic individuals (and their parents) perceive risk very differently: a ‘one in a million’ who will die from anaphylaxis. Indeed, the adverse impact of a diagnosis of food allergy on health-related quality of life is greater than that seen in diabetes and other chronic diseases. These data are perhaps best framed in the context of safety-netting: just as we manage everyday risks (such as driving, with safety standards on cars, airbags and crumple zones, adhering to a highway code), can we help our patients and their families take a similar approach to the food allergy, with safety-netting allowing affected individuals to lead as normal a life as possible?

DIAGNOSIS OF ANAPHYLAXIS
Anaphylaxis has been defined as a systemic or multi-organ allergic reaction; however, not all systemic reactions are anaphylaxis. For example, many reactions have only cutaneous manifestations (eg, generalised urticaria)—clearly a systemic phenomenon, but (in the absence of other symptoms) not anaphylaxis according to most guidelines. In practice, anaphylaxis in the UK (and also Australia) is characterised by the presence of ‘Airway/Breathing/Circulation’ (respiratory or cardiovascular) symptoms as part of an allergic reaction. Skin or mucosal changes alone are not a sign of an anaphylactic reaction.

There are two areas of potential controversy: the most common criteria to diagnose anaphylaxis are those developed by the National Institute of Allergy and Infectious Diseases (NIAID) and subsequently adopted by the World Allergy Organisation (box 1), which were designed to capture 95% of cases. However:

1. According to criterion 2, skin and gut symptoms together constitute anaphylaxis. However, the prevailing consensus in the UK (and Australia) with respect to food-induced reactions is that skin and gut symptoms, in the absence of respiratory or cardiovascular symptoms, are not anaphylaxis. For food, gastrointestinal symptoms are caused by the presence of local allergen in the gut rather than a systemic reaction. This is in contrast to venom-induced reactions, where the presence of gastrointestinal symptoms (eg, vomiting) would constitute anaphylaxis (as the gut is remote from the site of allergen exposure). There is also no consensus as to what constitutes persistent gut symptoms. This distinction is important, as many food-induced reactions are classified as anaphylaxis in the USA (and therefore should be treated with epinephrine), but not in the UK and Australia, something important to consider when making comparisons to US data.

2. Fatal (and in our experience, near-fatal) anaphylaxis reactions often present as acute bronchoconstriction without any other symptoms being
Clinical criteria for the diagnosis of anaphylaxis

Anaphylaxis is highly likely when any one of the following three criteria is fulfilled:
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue or both (e.g., generalised urticaria, itching or flushing, swollen lips–tongue–uvula) and at least one of the following:
   a. Respiratory compromise (e.g., dyspnoea, wheeze-bronchospasm, stridor, reduced peak flow, hypoxaemia)
   b. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia (collapse), syncope, incontinence) OR
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):
   a. Involvement of the skin–mucosal tissue
   b. Respiratory compromise
   c. Reduced blood pressure or associated symptoms
   d. Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting) OR
3. Reduced blood pressure after exposure to known allergen for that patient (minutes to several hours)

Myth 2: ‘There are no hives so it can’t be anaphylaxis’
Cutaneous symptoms (most commonly urticaria or ‘hives’) are absent in around 10% of anaphylaxis reactions and where present may be delayed in onset. This is consistent with a case series of six paediatric fatalities due to food anaphylaxis, where only one child had evidence of skin involvement: the lack of skin signs may have delayed diagnosis and appropriate treatment with epinephrine, contributing to the fatal outcome.

The Australasian Society of Clinical Immunology and Allergy (ASCIA) recently issued new guidelines, which define anaphylaxis as:
- Any acute onset illness with typical skin features (urticarial rash or erythema/flushing, and/or angio-oedema), PLUS involvement of respiratory and/or cardiovascular and/or persistent severe gastrointestinal symptoms; or
- Any acute onset of hypotension or bronchospasm or upper airway obstruction where anaphylaxis is considered possible, even if typical skin features are not present.

These criteria better reflect increasing recognition that cutaneous manifestations are often absent or appear late in near-fatal and fatal anaphylaxis.

The safe management of anaphylaxis depends on early recognition and treatment with intramuscular epinephrine. The British Society for Allergy and Clinical Immunology (BSACI), in conjunction with the Royal College of Paediatrics and Child Health, has recently updated its Allergy Management Plans for children (Figure 1), highlighting the potential for skin symptoms to be absent in anaphylaxis.

Myth 3: ‘No trigger for the reaction is identified, therefore it is not anaphylaxis’
Anaphylaxis is a clinical diagnosis. The most common trigger in young people is food: symptoms typically begin within 15–30 min of exposure and progress rapidly. Other triggers, such as medication or insect stings, are far less common in children.

In around 20% of cases, no trigger is identified; this is known as idiopathic anaphylaxis. Many such reactions will be due to undisclosed or ‘hidden’ food allergens. Identifying the culprit allergen can be challenging and referral to an allergy specialist is advised. A thorough review of the circumstances surrounding the reaction including a detailed dietary history supported by ingredients lists is likely to be required. Of note, if a child is consuming a food regularly without problem, it is unlikely to be the cause. This might seem obvious, but dietary manipulation along these lines are often recommended by non-specialists for idiopathic, non-anaphylaxis reactions presenting with only skin symptoms: such episodes are generally due to immune activation (often viral-triggered) rather than allergen exposure.

The most common food trigger for fatal anaphylaxis in children in the UK is milk, followed by peanut and tree nuts. While there is broad public recognition of the risks posed by nuts, cow’s milk allergy is often perceived as being less severe. However, milk allergy persisting into school age is often associated with other coexisting atopies (such as asthma) and more severe reactions, particularly in the 30%–40% of milk-allergic children who are unable to tolerate milk in well-baked foods (such as biscuits or cakes). Such exposure often results in delayed reactions which mimic asthma; under such circumstances, it may not be obvious that the child has been exposed to milk. Therefore, always consider anaphylaxis in someone with a known food allergy who has sudden breathing difficulty.

Laboratory tests (such as mast cell tryptase, MCT) may support a diagnosis of anaphylaxis, but these are not specific for anaphylaxis, nor are results available quick enough to impact on acute management. Measuring MCT may be helpful where the cause of the reaction is unclear: a serum sample should be collected within 15–180 min of symptom onset, with a further convalescent sample at least 6 hours later. However, MCT is often not raised in food-induced reactions, even in the most severe and fatal reactions. In a Canadian study, only 19.2% of children presenting with anaphylaxis had elevated MCT; even with severe reactions (cyanosis, hypoxia, respiratory arrest, hypotension, loss of consciousness), MCT was only raised in 50% of cases. A negative MCT does not, therefore, rule out anaphylaxis.

**ACUTE MANAGEMENT**

Epinephrine is the first-line treatment for anaphylaxis according to all guidelines. It has both α-sympathomimetic and β-sympathomimetic actions, causing peripheral vasoconstriction, increased cardiac output and bronchodilation; importantly, it is the only drug that inhibits the further release of inflammatory mediators from mast cells and basophils.

Myth 4: ‘Epinephrine is dangerous’
Epinephrine given by intramuscular injection into the outer mid-thigh is very safe and starts to work within minutes. Epinephrine can either be injected using a needle–syringe (using 1:1000 epinephrine, which results in a lower volume, less painful
injection than if using 1:10 000) or by autoinjector device (eg, Emerade, EpiPen, Jext). Where an autoinjector is used, note that both EpiPen and Jext are only available in 150 µg and 300 µg doses, which means that the 300 µg is effectively an underdose in someone over 30 kg (this may explain why some patients require a second epinephrine dose). Younger children should be transitioned to a 300 µg dose when their body weight is >25 kg, and some centres advocate doing so from 20 kg. Around 10%–20% of patients report transient effects including pallor, anxiety, palpitations, dizziness and headache (although these symptoms may also be due to the reaction and/or the patient’s own endogenous epinephrine production).
Epinephrine is underused in the treatment of anaphylaxis, both prehospital and in emergency departments. Further intramuscular doses of epinephrine should be administered in the event of persisting respiratory or cardiovascular symptoms. Epinephrine can and should be repeated after 5 min; the administration of other medication such as antihistamines or steroids must not cause delay or distraction, as these are not first-line (or even second-line) treatments for anaphylaxis. An alternative summary of anaphylaxis treatment, consistent with national and international guidelines, is shown in figure 2B.

**Myth 5: ‘Antihistamines can be used to treat anaphylaxis initially; epinephrine is only needed if symptoms worsen’**

Histamine is one of many inflammatory mediators released during anaphylaxis. Oral antihistamines take around 30 min for onset of effect; intravenous chlorphenamine has a faster onset, but can cause hypotension. Antihistamines are not effective against anaphylaxis: their prophylactic use during controlled immunotherapy does not prevent anaphylaxis, and any apparent response during acute management of reactions is most likely due to the patient’s own endogenous epinephrine. Antihistamines have now been relegated to third-line therapy in international guidelines; their use is limited to the relief of cutaneous symptoms and should never delay the administration of epinephrine or fluid resuscitation during patient stabilisation.

**Myth 6: ‘Corticosteroids prevent delayed or biphasic reactions in anaphylaxis’**

Historically, corticosteroids have been used to prevent protracted and biphasic reactions (the latter defined as a recurrence of symptoms within 72 hours of initial anaphylaxis, without re-exposure to the trigger). However, this has never been tested in a randomised clinical trial; more recent evidence has cast doubt over their efficacy. A recent systematic review and meta-analysis included 27 studies with 4114 anaphylaxis cases, of whom 192 (4.7%) had biphasic reactions. Steroid administration did not affect the likelihood of a late phase reaction (OR 1.52, 95% CI 0.96 to 2.43). In fact, there was a non-significant trend towards increased risk, although this is probably because steroid use was more common with severe reactions. Biphasic reactions were more common where hypotension was present at initial reaction (OR 1.52, 95% CI 1.14 to 2.04). In fact, there was a non-significant trend towards increased risk, although this is probably because steroid use was more common with severe reactions. Biphasic reactions were more common where hypotension was present at initial reaction (OR 1.52, 95% CI 1.14 to 2.04). In fact, there was a non-significant trend towards increased risk, although this is probably because steroid use was more common with severe reactions. Biphasic reactions were more common where hypotension was present at initial reaction (OR 1.52, 95% CI 1.14 to 2.04). In fact, there was a non-significant trend towards increased risk, although this is probably because steroid use was more common with severe reactions. Biphasic reactions were more common where hypotension was present at initial reaction (OR 1.52, 95% CI 1.14 to 2.04).
management plan and rescue medication (including epinephrine autoinjectors) in place.

**MANAGING CHILDREN AT RISK OF ANAPHYLAXIS**

Although research in ongoing into potential treatments for food allergy, the mainstay of management remains dietary avoidance and provision of a management plan/rescue medication in the event of accidental reactions.

**Myth 7: ‘Only children who have had anaphylaxis need an epinephrine autoinjector’**

Allergy skin prick tests and/or allergen-specific IgE blood tests do not predict reaction severity, and anaphylaxis can occur in patients with high, low and even negative tests. A recent European Consensus concluded that it is very difficult if not impossible to accurately predict who is at risk of severe anaphylaxis: a number of risk factors acting together are involved (figure 3).9

Clearly someone with previous anaphylaxis is at risk of subsequent anaphylaxis. However, most children who present with anaphylaxis as their initial reaction do not experience further anaphylaxis. Ewan and Clark followed up 747 allergic children, of whom 220 had initial anaphylaxis to peanut/tree nuts; 25% had further accidental reactions over a median 3-year follow-up, with only one experiencing further anaphylaxis.33 Other studies report a higher rate of anaphylaxis in those with initial mild reactions. In a UK survey of 969 young people attending allergy clinics, 48% had experienced an accidental reaction in the previous year, with 245 (25%) having anaphylaxis.6 However, the occurrence of anaphylaxis is likely to depend on a number of factors, including dose or level of exposure34 (figure 3). In a unique study of 89 children with suspected peanut allergy, Wainstein et al demonstrated that up to 75% will have anaphylaxis if exposed to sufficient peanut at challenge.35 Thus, lack of prior anaphylaxis is more likely due to insufficient exposure rather than some inherent lack of predisposition. Importantly, there are no data indicating that allergic reactions get worse with each subsequent exposure. Nor is there any evidence to suggest that anaphylaxis risk ‘runs in the family’.

Various risk factors for severe anaphylaxis have been proposed, based on limited case series of fatal anaphylaxis. Interestingly, food-induced anaphylaxis is most common in the 0–5 age group, but death from anaphylaxis in this age group is rare.2 Teenagers and young adults appear to have an age-dependent predisposition towards severe outcomes, which cannot be easily explained by risk-taking behaviours.2 Asthma is considered a risk factor; however, in the UK Fatal Anaphylaxis Registry, 22% of cases did not have a prior diagnosis of asthma.2 Around 50% of children with food allergies have asthma: the vast majority will never have a severe allergic reaction, thus asthma has poor predictive value for severe reactions (although this does not negate the imperative to improve asthma control in food-allergic individuals as a means of reducing risk).9

Delays in treating with epinephrine are a risk factor for fatal outcome10 36: it is this, as well as our inability to predict severe reactions, which drives the provision of epinephrine autoinjectors. A summary of recent guidelines on who should be prescribed autoinjectors is summarised in table 1. Healthcare professionals must consider the patient/family preference: if prescription boosts patient confidence and allows them to lead a less restrictive life, then autoinjectors should be part of the management plan. However, this requires actual carriage: the autoinjectors need to be available at all times, otherwise prescription is pointless.

Controversy exists over the number of autoinjectors to be prescribed. The BSACI and ASCIA in general recommend one device (for school children, one device for home and a second for school, while in the USA, physicians will generally prescribe two devices).10 17 In 2014, following an extensive review of epinephrine autoinjectors prompted by a coronial inquest, the Medicines and
Review

Table 1  Factors to be considered as part of the risk assessment on whether to prescribe epinephrine autoinjectors

<table>
<thead>
<tr>
<th>UK (BSACI)</th>
<th>Europe (EAACI)</th>
<th>Australia (ASCIA)</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous history</td>
<td>► Anaphylaxis and at risk of ongoing exposure</td>
<td>► Anaphylaxis</td>
<td>► Anaphylaxis and at ongoing risk of exposure</td>
</tr>
<tr>
<td></td>
<td>► Mild reaction to ‘trace’ amount of allergen</td>
<td>► Mild reaction to ‘trace’ amount of allergen</td>
<td>► Generalised urticaria alone without anaphylaxis due to insect sting in adults</td>
</tr>
<tr>
<td></td>
<td>► History of cofactors (eg, exercise) impacting on reaction severity</td>
<td>► Venom allergy in adults with systemic symptoms</td>
<td></td>
</tr>
<tr>
<td>Allergen-specific risk factors</td>
<td>► High-risk allergens, for example, nuts</td>
<td>► High-risk allergens, for example, nuts</td>
<td>► High-risk allergens, for example, nuts, seafood</td>
</tr>
<tr>
<td>Patient-specific risk factors</td>
<td>► Teenage/young adults</td>
<td>► Teenager or young adult with a food allergy*</td>
<td>► Teenagers and young adults with food allergy</td>
</tr>
<tr>
<td></td>
<td>► Food allergy* to high-risk allergens (eg, nuts) and other risk factors (eg, asthma)</td>
<td>► Food allergy* and coexisting unstable or moderate–severe, persistent asthma</td>
<td>► Food allergy* and coexisting unstable or moderate–severe, persistent asthma</td>
</tr>
<tr>
<td></td>
<td>► Raised baseline serum tryptase</td>
<td>► Underlying mast cell disorders or raised baseline serum tryptase</td>
<td>► Underlying mast cell disorders (eg, systemic mastocytosis or raised baseline serum tryptase)</td>
</tr>
<tr>
<td></td>
<td>► Limited access to emergency medical care, for example, remote location, social factors</td>
<td>► Remote from medical help</td>
<td>► Limited access to emergency medical care, for example, remote location, foreign travel</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>► Cardiovascular disease</td>
</tr>
</tbody>
</table>

Factors in bold are specified as ‘absolute’ (EAACI) or ‘recommended’ (ASCIA) indications.

*Excluding pollen food allergy syndrome.

ASCI, Australasian Society of Clinical Immunology and Allergy; BSACI, British Society for Allergy and Clinical Immunology; EAACI, European Academy of Allergy and Clinical Immunology.

Healthcare products Regulatory Agency (MHRA) issued guidance that individuals at risk of anaphylaxis should carry two epinephrine autoinjectors at all times due to ‘uncertainties about the site of drug delivery and the speed of epinephrine action within the body’, which, together with device misuse or malfunction, might result in a second dose being needed. The BSACI guidance (issued after the 2014 statement) recommends a single device on the basis that one dose is usually effective for most reactions. The MHRA recently reiterated its policy, in line with new Department of Health guidance for school children at risk of anaphylaxis. The MHRA review also addressed a concern that in some individuals (predominantly adolescent and adult women), the needle length in some autoinjectors may be insufficient to deliver an intramuscular (rather than subcutaneous) injection, although data to inform this are limited. At the current time, prescribing practice remains divided among UK healthcare professionals.

Myth 8: ‘Epinephrine autoinjectors are overprescribed and overused in anaphylaxis’

Autoinjectors are underused to treat anaphylaxis in the community. In a study of infants aged 3–15 months with anaphylaxis (US definition), epinephrine was administered in under one-third, most commonly because the caregiver did not recognise the severity of reaction or the autoinjector was not available. In a UK study, only 16.7% of young people used an autoinjector to treat anaphylaxis, the most common reason being they did not recognise that the reaction needed treatment with epinephrine. A Scottish study among adolescents with previous anaphylaxis reported a number of barriers to the effective use of autoinjectors, including failure to recognise anaphylaxis, uncertainty and fear over how and when to use the autoinjector, and lack of carriage due to size/design. In the USA, these issues have led to some management plans (by FARE) offering the suggestion to use an epinephrine autoinjector for all reactions regardless of severity, but this remains controversial and is not accepted as good practice among many healthcare professionals. It must be noted that anaphylaxis morbidity/mortality is no lower in the USA compared with UK and Australia where epinephrine is only recommended for reactions with respiratory or cardiovascular involvement.

Myth 9: ‘Prescription of an epinephrine autoinjector in isolation is life-saving’

Optimal management of food-allergic patients and treatment of anaphylaxis has many facets and is not limited to a prescription for an epinephrine autoinjector. Improving patient/carer knowledge on the recognition and treatment of anaphylaxis, and addressing the complex psychosocial dimensions of allergic emergencies, form the cornerstone of successful anaphylaxis management. One-third of fatalities in the UK occur despite timely epinephrine administration. Epinephrine autoinjectors potentially buy valuable minutes while an emergency medical response is summoned. Such devices need to be prescribed as part of a comprehensive management plan, which includes advice on dietary avoidance and on when to administer epinephrine. Patients and their families need to be told to use their autoinjector in the event of any respiratory symptoms, where anaphylaxis might be the cause, irrespective of severity. Patients with asthma may not realise the importance of this; they may perceive mild wheezing following food allergen exposure as equivalent to their routine symptoms. Patients and their families ‘need to be provided with more...
constructive strategies and support’ than merely being told to ‘use your pen’.42

The BSACI management plans are available for download online (http://www.bsaci.org/about/pag-allergy-action-plans-for-children/) and were recently updated to take into account changes in UK-wide legislation allowing the use of ‘spare’ epinephrine autoinjectors in schools. The BSACI plans, correctly completed, meet the requirements of the legislation and UK healthcare professionals are encouraged to use these plans where possible. Further information is available online (www.sparepensinschools.uk).

Correct positioning of the patient is important in anaphylaxis,8 25 something highlighted in MHRA guidance. Case series have highlighted the potential for a change in posture (eg, from sitting or lying to standing) to trigger decompensation and fatal event in some patients. Lying the patient supine with the lower limbs elevated will increase venous return and cardiac output. Patients with respiratory symptoms can be allowed to sit if this improves comfort, with their lower limbs elevated where possible. Sudden standing must be avoided, and patients with anaphylaxis must not be instructed to walk to a first aid room to use their autoinjector, as this may increase the risk of death.8 25 36

| Myth 1: Anaphylaxis often results in death | Anaphylaxis can be life-threatening, but the majority of reactions do not result in severe outcomes |
| Myth 2: There are no hives so it can’t be anaphylaxis | Cutaneous symptoms (most commonly urticaria or ‘hives’) are absent in around 10% of anaphylaxis reactions |
| Myth 3: No trigger for the reaction is identified, therefore it is not anaphylaxis | In around 20% of cases, no trigger is identified; this is known as idiopathic anaphylaxis |
| Myth 4: Epinephrine is dangerous | Epinephrine given by intramuscular injection into the outer mid-thigh is very safe |
| Myth 5: Antihistamines can be used to treat anaphylaxis initially; epinephrine is only needed if symptoms worsen | Epinephrine, not antihistamines, is the first-line treatment for anaphylaxis |
| Myth 6: Corticosteroids prevent delayed or biphasic reactions in anaphylaxis | There is insufficient evidence to support the use of corticosteroids prevent delayed or biphasic reactions in anaphylaxis |
| Myth 7: Only children who have had anaphylaxis need an epinephrine autoinjector | It is very difficult—if not impossible—to accurately predict who is at risk of severe anaphylaxis |
| Myth 8: Epinephrine autoinjectors are overprescribed and overused in anaphylaxis | Autoinjectors are underused to treat anaphylaxis in the community |
| Myth 9: Prescription of an epinephrine autoinjector in isolation is life-saving | Optimal management of food allergic patients and treatment of anaphylaxis has many facets and is not limited to a prescription for an epinephrine autoinjector |
| Myth 10: MMR and influenza vaccination are contraindicated in patients with previous anaphylaxis to egg | Both vaccines are safe to administer in egg-allergic children, including those with previous anaphylaxis |

Myth 10: ‘MMR and influenza vaccination are contraindicated in patients with previous anaphylaxis to egg’
A common misconception is that the influenza and measles, mumps, rubella (MMR) vaccines cannot be given to egg-allergic children, in particular those with previous anaphylaxis. The MMR vaccine is grown in chick fibroblast cell lines and does not contain detectable egg protein. Egg allergy, however severe, is not a contraindication.43 44 Influenza vaccines are prepared from viruses grown in embryonated hen’s eggs and can contain very low levels of ovalbumin. However, recent data have confirmed that both injected and intranasal forms of the vaccine are safe in egg-allergic children, including those with previous anaphylaxis.43 44 The ‘Green Book’45 46 and US guidelines44 now advise that these vaccines can be administered in primary care (or, in the case of the intranasal vaccine, schools), with the usual precautions taken for any vaccination. The only exception is those with previous life-threatening reactions to egg requiring intensive care, in whom there is little safety data (such reactions to egg are vanishingly rare); in any event, these patients (and their carers) may be better reassured if the vaccine is administered in hospital.

In contrast, yellow fever vaccine does contain small amounts of egg protein and has been reported to trigger anaphylaxis in some egg-allergic individuals. Desensitisation protocols for use in specialist centres are available,47 but administration is complicated by the need for such centres to be authorised to provide WHO certification. Currently, the authors are aware of only one UK paediatric centre (Evelina Hospital, London) where WHO certification can be issued following successful administration.

CONCLUSIONS
Anaphylaxis is a severe, potentially life-threatening systemic allergic reaction, which constitutes a clinical emergency. Common misconceptions regarding anaphylaxis are summarised in table 2. Prompt assessment and management are essential, as delays in treatment are associated with fatal outcomes. Anaphylaxis is primarily a clinical diagnosis: patients/carers and health professionals must be appropriately trained to recognise and institute appropriate treatment with intramuscular epinephrine, as part of a comprehensive management plan. Epinephrine is the first-line treatment for anaphylaxis, but is underused. Changes in posture have been documented as a trigger for decomposition and fatal anaphylaxis. New management plans incorporating this advice, and which allow the use of ‘spare’ autoinjectors in schools, are available from the BSACI and via www.sparepensinschools.uk website.

Correction notice This paper has been corrected since it was published Online First. The BSACI/RCPCH has just updated its Allergy Plans and so figure 1 has been replaced with the new plan.

Contributors KA and PJT jointly wrote the manuscript and approved the final version.

Funding PIT is in receipt of a Clinician Scientist award funded by the UK Medical Research Council (reference MRK10468/1).

Competing interests PJT is a co-led a taskforce of healthcare professionals (including the RCPCH) and representatives of patient support organisations, which worked with the UK Departments of Health to introduce legislation allowing the provision of ‘spare’ emergency adrenaline autoinjectors in schools, and helped develop guidance around this including the www.sparepensinschools.uk website.

Patient consent Not required.
Provenance and peer review  Commissioned; externally peer reviewed.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

REFERENCES
32 NICE. Anaphylaxis Guidelines. www.nice.org.uk/guidance/CG134